← Back to Screener
MIRA Pharmaceuticals, Inc. Common Stock (MIRA)
Price$1.00
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-40.36%
Price vs S&P 500 (4W)1.33%
VGM Score34.51
Market Capitalization$42.02M
All Metrics
Book Value / Share (Quarterly)$0.22
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.10
Price vs S&P 500 (YTD)-41.93%
EPS (TTM)$-0.32
10-Day Avg Trading Volume0.18M
EPS Excl Extra (TTM)$-0.32
EPS (Annual)$-0.44
ROI (Annual)-100.49%
Cash / Share (Quarterly)$0.22
ROA (Last FY)-94.13%
EBITD / Share (TTM)$-0.33
Cash Flow / Share (Annual)$-0.11
P/B Ratio4.49x
P/B Ratio (Quarterly)4.81x
Net Income / Employee (Annual)$-3,480,800
Net Interest Coverage (TTM)-2.47x
ROA (TTM)-135.02%
EPS Incl Extra (Annual)$-0.44
Current Ratio (Annual)15.75x
Quick Ratio (Quarterly)81.97x
3-Month Avg Trading Volume0.15M
52-Week Price Return-27.01%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.55
52-Week High$2.45
EPS Excl Extra (Annual)$-0.44
26-Week Price Return-32.43%
Quick Ratio (Annual)15.71x
13-Week Price Return-15.25%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)82.16x
Enterprise Value$37.21M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.26
3-Month Return Std Dev83.01%
Net Income / Employee (TTM)$-3,269,600
ROE (Last FY)-100.49%
Net Interest Coverage (Annual)-33.84x
EPS Basic Excl Extra (Annual)$-0.44
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.32
ROI (TTM)-140.83%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$-0.04
Price vs S&P 500 (52W)-51.37%
Year-to-Date Return-33.77%
5-Day Price Return-4.76%
EPS Normalized (Annual)$-0.44
ROA (5Y Avg)-298.63%
Month-to-Date Return-5.66%
EBITD / Share (Annual)$-0.44
EPS Basic Excl Extra (TTM)$-0.32
P/TBV (Quarterly)5.96x
P/B Ratio (Annual)6.08x
Book Value / Share (Annual)$0.25
Price vs S&P 500 (13W)-23.51%
Beta1.62x
Revenue / Share (TTM)$0.00
ROE (TTM)-140.83%
52-Week Low$0.90
mGradeD
vgmGradeD
Show chart for
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
MIRAMIRA Pharmaceuticals, Inc. Common Stock | — | — | D | $1.00 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Mira Pharmaceuticals is a pre-clinical-stage pharmaceutical company developing treatments for neurologic and neuropsychiatric disorders. The company's lead program, MIRA-55, is an oral cannabinoid candidate in development for anxiety and cognitive decline associated with early-stage dementia.